

INTERNATIONAL SEARCH REPORT

PCT/US2004/030831

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/44 C12N15/30 A61K39/018 G01N33/569 C07K16/20
C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 2 January 2003 (2003-01-02), "EST628751 TpMugugaSh01 Theileria parva cDNA clone TPFAN22, mRNA sequence." XP002318733 retrieved from EBI accession no. EM_EST:BQ545112 Database accession no. BQ545112 the whole document ----- -/--	17-22, 25-28, 30-33

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

7 June 2005

Date of mailing of the international search report

15. 07. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Huber, A

INTERNATIONAL SEARCH REPORT

PCT/US2004/030831

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MORRISON W IVAN ET AL: "Theileriosis: Progress towards vaccine development through understanding immune responses to the parasite" VETERINARY PARASITOLOGY, vol. 57, no. 1-3, 1995, pages 177-187, XP002310754 ISSN: 0304-4017 cited in the application page 184, last paragraph - page 185, paragraph 1 -----	1
A	GERHARDS JOACHIM ET AL: "Sequence and expression of a 90-kilodalton heat-shock protein family member of Theileria parva" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 68, no. 2, 1994, pages 235-246, XP002310752 ISSN: 0166-6851 the whole document -----	1
A	US 5 273 744 A (NANTULYA VINAND M ET AL) 28 December 1993 (1993-12-28) cited in the application column 3, line 50 - column 4, line 4; claims 1-14 -----	1

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-9, 17-21, 29-62 (all partially); 10, 13-16, 22, 25-28 (completely)

Isolated polypeptide Tp2 comprising a sequence represented by SEQ ID NO: 1 and the antigenic fragments SEQ ID NOs: 4, 5, 6 and 7, pharmaceutical or immunogenic composition or vaccine comprising said polypeptide, isolated polynucleotide comprising SEQ ID NO. 25, 28, 29, 30 or 31; pharmaceutical composition comprising said polynucleotide, vector comprising said polynucleotide, host cell comprising said vector, method of producing a polypeptide, comprising culturing said host cell, antibody specific for the polypeptide having SEQ ID NO: 1 or 4-7, kit comprising said antibody, method for protecting an animal against infection by T. parva, comprising administration of said polypeptide or of said host cell, method of detecting protozoan infection, method for preparing a polyclonal or monoclonal antibody against said polypeptide, method for identifying T. parva in a sample.

2. claims: 1-9, 17-21, 29-62 (all partially); 11, 23 (completely)

same as (1), but polypeptide Tp3 comprising a sequence represented by SEQ ID NO: 2, polynucleotide comprising SEQ ID NO: 26.

3. claims: 1-9, 17-21, 29-62 (all partially), 12, 24 (completely)

as (1), but polypeptide Tp6 comprising SEQ ID NO: 3 and polynucleotide comprising SEQ ID NO. 27.

INTERNATIONAL SEARCH REPORT

PCT/US2004/030831

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5273744	A	28-12-1993	NONE